Text Size

A post-marketing surveillance of 0.5% levofloxacin ophthalmic solution for external ocular infections

Kanda Y., Kayama T., Okamoto S., Hashimoto M., Ishida C., Yanai T., Fukumoto M., Kunihiro E.


  • 2008
  • Japanese Journal of Clinical Ophthalmology
View publication
  • Therapeutic Area

    Other

  • Categories

    Preclinical development

  • Affiliations

    PMS Group, Santen Pharmaceutical Co Ltd, Japan; Drug Safety Information Group, Santen Pharmaceutical Co Ltd, Japan; Post-Marketing Surveillance Group, Santen Pharmaceutical Co., Ltd., 3-9-19 Shimo-Shinjo, Osaka 533-8651, Japan

Related Publications

Enhancing Corneal Drug Penetration Using Penetratin for Ophthalmic Suspensions

Morofuji R.; Kudo K.; Honda T.; Kinugasa S.; Matsuo T.; Okabe K.


Use of Immunosuppression and the Risk of Subsequent Overall or Cancer Mortality

Kempen J.H.; Newcomb C.W.; Washington T.L.; Foster C.S.; Sobrin L.; Thorne J.E.; Jabs D.A.; Suhler E.B.; Rosenbaum J.T.; Sen H.N.; Levy-Clarke G.A.; Nussenblatt R.B.; Bhatt N.P.; Lowder C.Y.; Goldstein D.A.; Leiderman Y.I.; Acharya N.R.; Holland G.N.; Read R.W.; Dunn J.P.; Dreger K.A.; Artornsombudh P.; Begum H.A.; Fitzgerald T.D.; Kothari S.; Payal A.R.; Daniel E.; Gangaputra S.S.; Kaçmaz R.O.; Liesegang T.L.; Pujari S.S.; Khachatryan N.; Maghsoudlou A.; Suga H.K.; Pak C.M.; Helzlsouer K.J.; Buchanich J.M.


Exploring Cell-Penetrating Peptides as Penetration Enhancers in Eye Drop Formulations Using a Reconstructed Human Corneal Epithelial Model

Morofuji R.; Enomoto H.; Honda T.; Oyama Y.; Ishida R.; Kudo K.; Okabe K.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022